spinout
Claris GenomiX Seeks Commercialization Partners for Cancer Subtyping Tests, Starting With CRC
Premium
The University of Notre Dame spinout has developed molecular subtyping tests for colorectal and other cancers, and seeks partners to bring them to the clinic.
In addition to proving clinical utility, the startup will have to navigate issues of regulatory strategy, sequencing technology, and additional indications.
Delve Bio Raises $35M in Series A Financing to Develop Metagenomic Sequencing Diagnostics
The UCSF spinout's cofounders include Joe DeRisi and Charles Chiu, as well as Pardis Sabeti of Harvard University and the Broad Institute.
POC Genotyping Tests Based on Electromagnetic Detection Tech Step out From Stanford University Lab
Premium
Spinout Magic LifeScience is leading commercialization of the molecular diagnostic technology, but the tests are popping up in other clinical scenarios, too.
The lead investigators have also spun out a company, Isabl, aiming to make the approach available to the broader community.